Clinical Trials
56 trialsNCT04756037 2026-05-13
SERENE
Sumitomo Pharma Switzerland GmbH
Phase 3 Completed
NCT04272216 2025-09-09
RAVI Registry
Terumo Medical Corporation
Completed
NCT03194646 2025-07-28
ASTEROID 6
Bayer
Phase 3 Terminated
NCT03271489 2025-07-22
Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
AbbVie
Phase 3 Completed
NCT03751124 2024-06-25
Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Myovant Sciences GmbH
Phase 3 Completed
NCT03412890 2024-05-09
LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Myovant Sciences GmbH
Phase 3 Completed
NCT03400943 2023-05-03
Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)
Bayer
Phase 3 Terminated
NCT03400956 2022-06-30
Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)
Bayer
Phase 3 Terminated
NCT03103087 2022-04-20
LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Myovant Sciences GmbH
Phase 3 Completed
NCT03049735 2022-04-19
LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Myovant Sciences GmbH
Phase 3 Completed
NCT03886220 2022-03-31
A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
AbbVie
Phase 4 Completed
NCT00731341 2021-07-19
Hysteroscopic Cryomyolysis for the Treatment of Submucosal Leiomyomata
Boston Scientific Corporation
Phase NA Completed
NCT01441635 2021-07-13
Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids
AbbVie
Phase 2 Completed
NCT02691494 2021-07-13
Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)
AbbVie
Phase 3 Completed
NCT02925494 2021-07-13
An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
AbbVie
Phase 3 Completed
NCT01817530 2020-07-21
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
AbbVie
Phase 2 Completed
NCT02654054 2020-06-29
Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
AbbVie
Phase 3 Completed
NCT02228174 2020-02-11
SONATA
Gynesonics
Phase NA Completed
NCT02844920 2019-09-20
OPEN
Gynesonics
Completed
NCT01629563 2019-09-04
PEARLIV
PregLem SA
Phase 3 Completed
NCT02811159 2019-06-27
An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Terminated
NCT02323646 2019-06-25
Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Completed
NCT02301897 2019-06-19
A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Completed
NCT00958334 2019-06-18
Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003
Repros Therapeutics Inc.
Phase 2 Completed
NCT00131365 2019-06-12
Magnetic Resonance (MR) Guided Focused Ultrasound Surgery of Uterine Fibroids
InSightec
Phase NA Completed
NCT02147158 2019-06-04
A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas
Allergan
Phase 3 Completed
NCT02147197 2019-04-30
A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas
Allergan
Phase 3 Completed
NCT02655224 2019-03-22
A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids
Takeda
Phase 3 Completed
NCT02655237 2019-03-22
A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids
Takeda
Phase 3 Completed
NCT01142791 2019-03-19
Safety Study of ExAblate for the Treatment of Uterine Fibroids
InSightec
Phase NA Completed
NCT01285960 2019-03-06
ExAblate UF V2 System for the Treatment of Symptomatic Uterine Fibroids
InSightec
Phase NA Completed
NCT00365989 2019-02-05
MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication
InSightec
Phase 3 Completed
NCT00730886 2018-08-15
ExAblate Treatment of Uterine Fibroids for Fertility Enhancement
InSightec
Phase NA Terminated
NCT02131662 2017-12-08
ASTEROID 1
Bayer
Phase 2 Completed
NCT01152112 2017-09-13
HOME
Hologic, Inc.
Phase NA Completed
NCT01369758 2017-09-13
MyoSure Hysteroscopic Tissue Removal System Registry Study
Hologic, Inc.
Phase NA Completed
NCT00891657 2017-09-07
Post Market Study for an Adhesion Barrier Following Laparoscopic Myomectomy
Integra LifeSciences Corporation
Phase NA Completed
NCT01842789 2017-08-18
TAG
Acessa Health, Inc.
Phase NA Terminated
NCT01946178 2017-05-30
Clinical Study of the Mirabilis High-Intensity Focused Ultrasound System for Non-Invasive Treatment of Uterine Fibroids
Mirabilis Medica, Inc.
Phase NA Completed
NCT01388907 2016-11-17
Efficacity Assessment of PREVADH® in Adhesion Prevention in Gynaecologic Surgery
Medtronic - MITG
Phase 4 Completed
NCT01675011 2016-03-11
Embozene Microspheres for Uterine Fibroid Embolization (UFE)
Boston Scientific Corporation
Phase NA Terminated
NCT01451424 2014-08-29
Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Completed
NCT00958893 2014-08-25
An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext
Repros Therapeutics Inc.
Phase 2 Terminated
NCT00683917 2014-08-21
Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Terminated
NCT00702702 2014-08-21
Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 3 Terminated
NCT00735553 2014-08-21
Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 3 Terminated
NCT00737282 2014-08-21
Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids
Repros Therapeutics Inc.
Phase 3 Terminated
NCT00785356 2014-08-21
Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 3 Terminated
NCT00853567 2014-08-21
Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 3 Terminated
NCT01069120 2014-08-21
Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 3 Terminated